Rivastigmine Tartrate Capsule
Product Images NDC 62756-147

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 62756-147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine-1-5mg (Rivastigmine 1 5mg)

Label for Rivastigmine Tartrate Capsules, 1.5 mg base strength, oral dosage form. The label shows a package containing 60 capsules. It is distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Ind. Ltd. in Gujarat, India. Storage instructions and usage cautions are included.*

FDA Label Image

Rivastigmine-3mg (Rivastigmine 3mg)

Rivastigmine Tartrate Capsules label showing 3 mg base strength, with 60 capsules in the package. Distributed by Sun Pharmaceutical Industries, Inc. in Cranbury, NJ, and manufactured by Sun Pharmaceutical Ind. Ltd. in Gujarat, India. Includes storage instructions and a barcode.*

FDA Label Image

Rivastigmine-4-5mg (Rivastigmine 4 5mg)

Rivastigmine Tartrate Capsules label showing 4.5 mg base strength, containing 60 capsules. Distributed by Sun Pharmaceutical Industries, Inc., New Jersey, and manufactured by Sun Pharmaceutical Ind. Ltd., Gujarat, India. Includes storage instructions and dosage note, with NDC 62756-147-86 and Sun Pharma logo.*

FDA Label Image

Rivastigmine-6mg (Rivastigmine 6mg)

Rivastigmine Tartrate Capsules label showing 6 mg equivalent base strength and package count of 60 capsules. Distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Ind. Ltd. in India. Includes storage instructions and note to see package insert for dosage information.*

FDA Label Image

Spl-rivastigmine-figure1 (Spl Rivastigmine Figure1)

A line graph titled 'Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment in Study 1' showing mean change in ADAS-cog scores with error bars over 0, 12, 18, and 26 weeks. It compares three groups labeled 6 to 12 mg, 1 to 4 mg, and Placebo, with the 6 to 12 mg group showing clinical improvement and the other groups showing clinical decline over time.*

FDA Label Image

Spl-rivastigmine-figure2 (Spl Rivastigmine Figure2)

A cumulative percentage graph showing patients completing 26 weeks of double-blind treatment with Rivastigmine Tartrate, comparing placebo, 1 to 4 mg/day, and 6 to 12 mg/day groups. The x-axis is change from baseline in ADAS-cog scores and the y-axis is cumulative percentage of patients. A table summarizes changes in ADAS-cog scores for each treatment group.*

FDA Label Image

Spl-rivastigmine-figure3 (Spl Rivastigmine Figure3)

Bar chart showing the frequency distribution of CIBIC-Plus scores at week 26 in Study 1 among patients. The x-axis lists CIBIC-Plus rating categories from "Markedly Improved" to "Markedly Worse." The y-axis shows the percentage of patients. Data is grouped into three categories: Placebo, 1 to 4 mg dosage, and 6 to 12 mg dosage, comparing patient response percentages across each CIBIC-Plus rating.*

FDA Label Image

Spl-rivastigmine-figure4 (Spl Rivastigmine Figure4)

A line graph titled 'Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment' showing mean change in ADAS-cog rating over 26 weeks. The graph compares three groups: 6 to 12 mg, 1 to 4 mg, and placebo. The vertical axis ranges from -3 to 2, indicating clinical improvement (negative change) and decline (positive change), while the horizontal axis shows weeks during treatment at 0, 12, 18, and 26 weeks.*

FDA Label Image

Spl-rivastigmine-figure5 (Spl Rivastigmine Figure5)

A cumulative percentage line graph showing patients completing 26 weeks of double-blind treatment with changes from baseline ADAS-cog scores. The graph compares three treatment groups: 6 to 12 mg, 1 to 4 mg, and placebo, plotting cumulative percentage of patients (0-100%) against change from baseline (-25 to 30). An inset table summarizes the percentage of patients by treatment group achieving change thresholds (-7, -4, 0).*

FDA Label Image

Spl-rivastigmine-figure6 (Spl Rivastigmine Figure6)

A bar chart titled 'Frequency Distribution of CIBIC-Plus Scores at Week 26 in Study 2' showing percentages of patients on the vertical axis and CIBIC-Plus ratings on the horizontal axis. Three groups are compared: Placebo, 1 to 4 mg, and 6 to 12 mg doses, represented by different shaded bars. The ratings range from Markedly Improved to Markedly Worse, illustrating the distribution of patient outcomes by treatment group.*

FDA Label Image

Spl-rivastigmine-figure7 (Spl Rivastigmine Figure7)

A line graph titled 'Time Course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment in Study 4'. It compares mean change from baseline ADAS-cog ratings between Rivastigmine Tartrate and placebo groups over 0, 8, 16, and 24 weeks of treatment. The vertical axis represents mean change (+/- SEM) with clinical improvement indicated at negative values and clinical decline at positive values. The Rivastigmine Tartrate group shows increasing clinical improvement over time, while placebo remains near baseline.*

FDA Label Image

Spl-rivastigmine-figure8 (Spl Rivastigmine Figure8)

A bar graph titled 'Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks of Treatment in Study 4' comparing percentages of patients by ADCS CGIC rating categories. The graph displays two groups: Rivastigmine Tartrate and Placebo, across seven rating categories from 'Markedly improved' to 'Markedly worse.' The vertical axis shows patient percentages, allowing comparison of treatment effects.*

FDA Label Image

Structure (Structure)

Chemical structure of Rivastigmine Tartrate, illustrating its molecular composition and arrangement of atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.